ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patientsFebruary 20, 2019ThrombosisPatient & Survivor Care
ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxabanFebruary 16, 2019Thrombosis
Impaired clot lysis associated with mild bleeding symptomsJanuary 27, 2019ThrombosisMixed TopicsBleeding Disorders
Anticoagulation shows promise in concurrent lupus nephritis, thrombotic microangiopathyJanuary 2, 2019Thrombosis
Phase 3 data support apixaban for cancer-associated VTEDecember 13, 2018Patient & Survivor CareThrombosis
